<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="17596">Inosine</z:chebi> is a naturally occurring <z:chebi fb="0" ids="33838">nucleoside</z:chebi> degraded from <z:chebi fb="3" ids="16335">adenosine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have demonstrated that <z:chebi fb="0" ids="17596">inosine</z:chebi> has potent immunomodulatory and neuroprotective effects </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we further investigated the inhibitory effects of <z:chebi fb="0" ids="17596">inosine</z:chebi> on platelet activation in vitro and in vivo, as well as in attenuating middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO)-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: <z:chebi fb="0" ids="17596">Inosine</z:chebi> concentration-dependently (0.5 to 6.0 mmol/L) inhibited platelet aggregation stimulated by <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="17596">Inosine</z:chebi> (1.5 and 3.0 mmol/L) inhibited <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> breakdown, [Ca+2]i, and TxA2 formation in human platelets stimulated by collagen (1 microg/mL) </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="17596">inosine</z:chebi> (1.5 and 3.0 mmol/L) markedly increased levels of cyclic guanylate monophosphate (<z:chebi fb="10" ids="17345">GMP</z:chebi>) and cyclic <z:chebi fb="10" ids="17345">GMP</z:chebi>-induced <z:chebi fb="1" ids="35620">vasodilator</z:chebi>-stimulated phosphoprotein Ser157 phosphorylation </plain></SENT>
<SENT sid="6" pm="."><plain>Rapid phosphorylation of a platelet protein of molecular weight 47,000 (P47), a marker of protein kinase C activation, was triggered by collagen (1 microg/mL) </plain></SENT>
<SENT sid="7" pm="."><plain>This phosphorylation was markedly inhibited by <z:chebi fb="0" ids="17596">inosine</z:chebi> (3.0 mmol/L) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="17596">Inosine</z:chebi> (1.5 and 3.0 mmol/L) markedly reduced <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> in collagen (1 microg/mL)-activated platelets </plain></SENT>
<SENT sid="9" pm="."><plain>In in vivo studies, <z:chebi fb="0" ids="17596">inosine</z:chebi> (400 mg/kg) significantly prolonged the latency period of inducing platelet plug formation in mesenteric venules of mice, and administration of 2 doses (100 mg/kg) or a single dose (150 mg/kg) of <z:chebi fb="0" ids="17596">inosine</z:chebi> significantly attenuated MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Platelet aggregation contributes significantly to MCAO-induced focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The most important findings of this study suggest that <z:chebi fb="0" ids="17596">inosine</z:chebi> markedly inhibited platelet activation in vitro and in vivo, as well as <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, <z:chebi fb="0" ids="17596">inosine</z:chebi> treatment may represent a novel approach to lowering the risk of or improving function in thromboembolic-related disorders and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion brain injury </plain></SENT>
</text></document>